» Articles » PMID: 30116722

Smurfs in Protein Homeostasis, Signaling, and Cancer

Overview
Journal Front Oncol
Specialty Oncology
Date 2018 Aug 18
PMID 30116722
Citations 61
Authors
Affiliations
Soon will be listed here.
Abstract

Protein ubiquitination is an evolutionary conserved highly-orchestrated enzymatic cascade essential for normal cellular functions and homeostasis maintenance. This pathway relies on a defined set of cellular enzymes, among them, substrate-specific E3 ubiquitin ligases (E3s). These ligases are the most critical players, as they define the spatiotemporal nature of ubiquitination and confer specificity to this cascade. Smurf1 and Smurf2 (Smurfs) are the C2-WW-HECT-domain E3 ubiquitin ligases, which recently emerged as important determinants of pivotal cellular processes. These processes include cell proliferation and differentiation, chromatin organization and dynamics, DNA damage response and genomic integrity maintenance, gene expression, cell stemness, migration, and invasion. All these processes are intimately connected and profoundly altered in cancer. Initially, Smurf proteins were identified as negative regulators of the bone morphogenetic protein (BMP) and the transforming growth factor beta (TGF-β) signaling pathways. However, recent studies have extended the scope of Smurfs' biological functions beyond the BMP/TGF-β signaling regulation. Here, we provide a critical literature overview and updates on the regulatory roles of Smurfs in molecular and cell biology, with an emphasis on cancer. We also highlight the studies demonstrating the impact of Smurf proteins on tumor cell sensitivity to anticancer therapies. Further in-depth analyses of Smurfs' biological functions and influences on molecular pathways could provide novel therapeutic targets and paradigms for cancer diagnosis and treatment.

Citing Articles

SMURF1-Induced Ubiquitination of FTH1 Disrupts Iron Homeostasis and Suppresses Myogenesis.

Xiong X, Li W, Yu C, Qiu M, Zhang Z, Hu C Int J Mol Sci. 2025; 26(3).

PMID: 39941157 PMC: 11818545. DOI: 10.3390/ijms26031390.


Smurf2 Suppresses Proliferation and Cell Cycle of Triple-Negative Breast Cancer Cells by Promoting the Polyubiquitination and Degradation of RPL35A.

Wei S, Liu Y, Wang Z, Wei T, Zhou W, Li W J Cell Mol Med. 2025; 29(2):e70394.

PMID: 39871432 PMC: 11772314. DOI: 10.1111/jcmm.70394.


NEDD4 family E3 ligases in osteoporosis: mechanisms and emerging potential therapeutic targets.

Wu H, Zuo J, Dai Y, Li H, Wang S J Orthop Surg Res. 2025; 20(1):92.

PMID: 39849530 PMC: 11761774. DOI: 10.1186/s13018-025-05517-5.


CAF-EVs carry lncRNA MAPKAPK5-AS1 into hepatocellular carcinoma cells and promote malignant cell proliferation.

Sheng L, Lin J, Zhang Y, Chen Y, Ye X, Wang X Commun Biol. 2024; 7(1):1711.

PMID: 39739005 PMC: 11685398. DOI: 10.1038/s42003-024-07428-3.


Targeting the SMURF2-HIF1α axis: a new frontier in cancer therapy.

Youssef E, Zhao S, Purcell C, Olson G, El-Deiry W Front Oncol. 2024; 14:1484515.

PMID: 39697237 PMC: 11652374. DOI: 10.3389/fonc.2024.1484515.


References
1.
Osmundson E, Ray D, Moore F, Gao Q, Thomsen G, Kiyokawa H . The HECT E3 ligase Smurf2 is required for Mad2-dependent spindle assembly checkpoint. J Cell Biol. 2008; 183(2):267-77. PMC: 2568023. DOI: 10.1083/jcb.200801049. View

2.
Kim K, Roberts C . Targeting EZH2 in cancer. Nat Med. 2016; 22(2):128-34. PMC: 4918227. DOI: 10.1038/nm.4036. View

3.
Gao Z, Xu M, Barnett T, Xu C . Resveratrol induces cellular senescence with attenuated mono-ubiquitination of histone H2B in glioma cells. Biochem Biophys Res Commun. 2011; 407(2):271-6. DOI: 10.1016/j.bbrc.2011.02.008. View

4.
Kim S, Jho E . The protein stability of Axin, a negative regulator of Wnt signaling, is regulated by Smad ubiquitination regulatory factor 2 (Smurf2). J Biol Chem. 2010; 285(47):36420-6. PMC: 2978571. DOI: 10.1074/jbc.M110.137471. View

5.
David D, Nair S, Pillai M . Smurf E3 ubiquitin ligases at the cross roads of oncogenesis and tumor suppression. Biochim Biophys Acta. 2012; 1835(1):119-28. DOI: 10.1016/j.bbcan.2012.11.003. View